A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

Sponsor
Hansoh BioMedical R&D Company
Study ID
NCT06926582
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • HS-10374 6mg tablets — DRUG
    Administered orally QD for 12 weeks
  • HS-10374-matched placebo tablets — DRUG
    Administered orally QD for 12 weeks

Study Details

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.

Key Dates

First listed
Apr 13, 2025
Start date
Apr 9, 2025
Status verified
Apr 2025
Primary completion
Jul 9, 2026
Completion
Dec 9, 2026

Study Design

Enrollment
305 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HS-10374 Dose 1
  • Experimental: HS-10374 Dose 2
  • Placebo Comparator: Placebo

Primary Outcome Measure

Proportion of patients achieving sPGA 0/1 with at least 2 points improvement from baseline at Week 12 [ Time Frame: Baseline to Week 12 ]

Central Contacts

Find similar trials

Nationwide
Psoriasis trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies